News Agency
The Times

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

  • Written by PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Trial results anticipated in early Q3 this year

SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept,...

Read more: Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion